Perspectives on the utility of moxidectin for the control of parasitic nematodes in the face of developing anthelmintic resistance.

This research highlights the increasing issue of resistance to macrocyclic lactone (ML) anthelmintics, medications used to treat parasitic worm infections in animals and humans. The article explores the potential benefits of using moxidectin (MOX), an anthelmintic that appears to continue working effectively even when parasitic resistance has developed against others in the ML class.

Introduction

• The research article discusses the severe problem of resistance against Macrocyclic lactone (ML) anthelmintics, key drugs employed for treating parasitic infections in humans and livestock.
• Resistance to MLs has become prevalent around the world, particularly among nematode parasites of small ruminants, but also increasingly in other animals like horses, cattle, and dogs.
• Resistance is even suspected in an infection affecting humans known as Onchocerca volvulus.

Use of Moxidectin

• Moxidectin (MOX) emerged as a useful anthelmintic after parasites began developing resistance to the avermectins, which is another sub-class of MLs.
• MOX typically proves more effective than avermectins when dealing with ML-resistant parasites.
• The study explores the potential for MOX to be a solution against drug-resistant parasitic infections, diving deep into its properties and differences from the avermectins.

Properties of Moxidectin

• MOX’s distinct pharmacokinetic profile differentiates it from other MLs: it is not easily removed by ABC efflux transporters, does not metabolize readily, and has a long half-life.
• Due to these properties, MOX’s effective concentrations can persist longer in the target hosts. Moreover, despite its potency, MOX has a high safety index, furthering its candidacy as a potent drug against resistant parasites.

Implications & Future Research

• Based on preliminary data, the study raises the possibility that anthelmintic resistance may be temporarily reversed if a high concentration of the medication can be sustained at the parasites’ site for an extended period.
• If MOX is administered at sufficiently high doses and in formulations that improve its persistence in the host, it could potentially control strains of parasites that are resistant to avermectins and other MLs.
• The research concludes with a review of MOX’s properties and the conditions under which it might be effectively employed against resistant parasites. It also suggests several areas for future exploration in this field.